Cervical Cancer Products
The Roche Cervical Cancer Portfolio gives you clearer, more definitive answers to help inform your patient care and management decisions.
The Roche Cervical Cancer Portfolio is a powerful combination of clinically validated tests that simplify prevention and management, while providing unprecedented efficiency to the process for risk assessment. Our cervical cancer product portfolio is rooted in science, consisting of molecular, cellular and tissue-based HPV screening and diagnostic tests.
Key Benefits of the Roche Cervical Cancer Portfolio
Simplifies screening, triage and diagnosis
Detects disease earlier
Ensures certainty of results
Unifies sample collection for HPV DNA, Pap or CINtec® PLUS Cytology
if she is at risk for cervical cancer with the cobas® HPV test
if she is progressing toward cervical cancer with CINtec® PLUS Cytology
if she has cervical precancer with CINtec® Histology